

PRESS RELEASE

Lyon, France
September 2026

Nemera is a world-leading provider of drug delivery device solutions and combination product services. Our mission of putting patients first drives us to design and manufacture devices that maximize treatment efficacy. From early device strategy to state-of-the-art manufacturing, we are committed to delivering the highest quality standards to our customers.

Nemera in figures:

€700 million in sales

3,300+ employees worldwide

7 manufacturing sites across 3 continents (North America, Europe, Latin America)

2 Innovation Centers

126 patent families supporting proprietary device platforms

60 Nemera devices used every second worldwide

400+ customers, with long-term partnerships exceeding 20 years with top customers

Contact Nemera

Coraline Cortot | Global
Communications Manager
+33 6 18 78 27 74 |
coraline.cortot@nemera.net

Nemera ©2026

Nemera expands production capacity in Ponts-et-Marais, France.

Nemera today inaugurated a new production facility in Ponts-et-Marais, France. Hall 3 will expand the production capacity of Nemera's Ponts-et-Marais and Le Tréport sites, support growing customer demand, and create up to 100 employees in the coming years.



Hall 3 will house the production equipment for the SP9 pump, along with other strategic manufacturing assets, enabling the consolidation of SP2 pump production at the Le Tréport site. This organization will further strengthen the complementarity between the two facilities while supporting their long-term development.

Covering a total surface area of 7,200 sqm, the new facility includes a 2,600 sqm ISO Class 8 cleanroom as well as dedicated logistics and technical areas. Equipped with state-of-the-art injection molding machines and high-speed assembly lines, Hall 3 will significantly increase Nemera's manufacturing capacity. Ultimately, the Le Tréport and Ponts-et-Marais sites combined will be able to produce up to 120 million additional devices annually to meet growing market demand. Built on a 46,000 sqm

site, the facility also benefits from available land reserves to support future phases of Nemera's industrial expansion.

Hall 3 has been designed in line with Nemera's highest sustainability standards. Building on the company's EcoVadis Gold Medal recognition, the site is targeting ISO 14001 and ISO 50001 certifications, reflecting Nemera's commitment to environmental stewardship and energy performance. Like all new facilities developed by the Group, Hall 3 has been designed with the objective of achieving a BREEAM Good rating, an internationally recognized benchmark for sustainable building design and construction. The facility incorporates high-efficiency energy systems, on-site photovoltaic power generation, and landscaped green areas that promote biodiversity. In addition, manufacturing processes rely exclusively on electricity, contributing to a lower carbon footprint. Through this new facility, Nemera reaffirms its commitment to combining industrial excellence, innovation, and responsible growth to support its customers while helping improve the lives of millions of patients worldwide.

Beyond its industrial impact, the project will also contribute to the economic vitality of the region. Approximately 100 employees are expected to work at the site within the next two years, while the expansion of Nemera's activities will create additional opportunities for local suppliers and business partners.

"Hall 3 marks a new milestone in the development of our operations in Normandy. We are proud to further strengthen our presence in the region and contribute to its economic vitality through this forward-looking project. This additional capacity will enable us to support our customers' growth, respond to increasing market demand, and continue delivering on our commitment to patients, who remain at the heart of everything we do," said Stéphane Thiaudière, Director of the Nemera Le Tréport and Ponts-et-Marais sites.

About Nemera

Nemera is a world-leading provider of drug delivery device solutions and combination product services. Our mission of putting patients first drives us to design and manufacture devices that maximize treatment efficacy. From early device strategy to state-of-the-art manufacturing, we are committed to delivering the highest quality standards to our customers.

Contact Nemera

Coraline Cortot

Global Communications Manager

+33 6 18 78 27 74 | coraline.cortot@nemera.net

For more information, visit:

www.nemera.net

<https://www.linkedin.com/company/nemera/>

<https://www.instagram.com/nemeratalent/>